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Chronic lymphocytic leukemia (CLL) is an incurable disease
with a heterogeneous clinical course. While some patients
require early treatment and rapidly succumb to the disease,
others have an indolent course that does not affect their life -
span.1 In the last decades, the aim of therapy for patients with
CLL has shifted from palliation2 to disease eradication, particu-
larly for younger patients who account for almost a third of the
entire population with this disease.3 Moreover, we are now
able to predict the outcome of these patients more accurately
using a plethora of prognostic markers such as molecular cyto-
genetics;4 point mutations in a variety of genes, including TP53,
NOTCH1, SF3B1 and POT1;5-9 DNA methylation,10
immunoglobulin heavy chain gene (IGHV) mutational sta-
tus;11,12 CD38 and ZAP-70 expression;12,13 serum β2-microglobu-
lin levels;14 and clinical stage;15,16 all of which have a significant
impact on time to first treatment, overall survival, treatment-
free survival or progression-free survival after therapy.
Modern chemoimmunotherapy regimens achieve much
higher complete response rates than conventional
chemotherapy, and a significant proportion of patients have
no detectable disease in peripheral blood or bone marrow
even when very sensitive immunophenotypic or molecular
methods are used to look for residual disease. These patients
are considered to have achieved a minimal residual disease
(MRD) negative status.17-20 Several phase II trials have demon-
strated that patients achieving MRD negativity have a signif-
icantly longer survival than those who remain MRD positive,
and this is true for patients treated with conventional
chemotherapy,21,22 monoclonal antibodies,23 chemoim-
munotherapy,24 or stem cell transplantation.25,26 Furthermore,
a phase III trial performed by the German CLL Study Group
(GCLLSG) recently revealed that patients obtaining MRD
negativity had significantly longer progression-free and over-
all survivals, irrespectively of the treatment received.18
Unfortunately, however, some of these studies were flawed
by inappropriate statistical analysis, particularly the meas-
urement of time-to-event outcomes from treatment initia-
tion.27
Furthermore, there are several caveats to the use of MRD
analysis in patients with CLL.28 First, CLL remains incurable
and at least 30% of patients who achieve MRD negativity after
front-line therapy with fludarabine-cyclophosphamide (FC) or
rituximab-FC eventually experience a disease relapse within 5
years.18 Secondly, unlike the situation in acute promyelocytic
leukemia or chronic myeloid leukemia,29,30 there is no formal
proof of a therapeutic benefit of re-treatment upon documen-
tation of MRD positivity after an initial MRD-negative
response compared to treatment at the time of clinical relapse.
In fact, very few studies have demonstrated a clear benefit
from MRD eradication or consolidation therapy in CLL,31,32 and
some of the strategies tested, although effective, resulted in sig-
nificant toxicity.33-35 Thirdly, it could be argued that MRD
assessment is simply a surrogate for evalution of other adverse
prognostic markers since, for instance, patients with a 17p
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A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual disease negative status after
therapy. We retrospectively evaluated the impact of minimal residual disease on the outcome of 255 consecutive
patients receiving any front-line therapy in the context of a detailed prognostic evaluation, including assessment of
IGHV, TP53, NOTCH1 and SF3B1 mutations. The median follow-up was 73 months (range, 2-202) from disease
evaluation. The median treatment-free survival durations for patients achieving a complete response without or
with minimal residual disease, a partial response and no response were 76, 40, 11 and 11 months, respectively
(P<0.001). Multivariate analysis revealed that three variables had a significant impact on treatment-free survival:
minimal residual disease (P<0.001), IGHV status (P<0.001) and β2-microglobulin levels (P=0.012). With regards to
overall survival, factors predictive of an unfavorable outcome were minimal residual disease positivity (P=0.014),
together with advanced age (P<0.001), unmutated IGHV status (P=0.001), TP53 mutations (P<0.001) and elevated
levels of β2-microglobulin (P=0.003). In conclusion, for patients requiring front-line therapy, achievement of minimal
residual disease negativity is associated with significantly prolonged treatment-free and overall survival irrespective
of other prognostic markers or treatment administered. 
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ABSTRACT
deletion have a higher probability of remaining MRD-posi-
tive after therapy compared to patients without this chro-
mosome abnormality.18 For all these reasons, current guide-
lines for the management of patients with CLL recommend
MRD assessment only within clinical trials with “curative
intention”.36
With all this facts in mind, we retrospectively evaluated
the impact of MRD on the outcome of patients with CLL
receiving any front-line therapy in the context of a very
detailed prognostic evaluation, including recently
described recurrent gene mutations.
Methods
Patients, data collection and response criteria
All patients in this study signed informed consent and were
recruited into the International Cancer Genome Consortium
Chronic Lymphocytic Leukemia (ICGC-CLL) project, which was
reviewed by our Institutional Review Board. From our database,
we identified 327 consecutive patients who received any front-line
therapy and were formally re-evaluated following National
Cancer Institute–Working Group (NCI-WG) criteria.36-38
Indications for treatment were also those recommended by the
NCI-WG.36-38 Patients were excluded from this analysis if they had
received therapy elsewhere (n=48) or were treated before 1990
(n=24). Thus, the final number of patients evaluated was 255. All
baseline characteristics were determined at the time of diagnosis
and, in those patients in whom these markers were not available
at that time, stored samples were used to obtain them a posteriori.
A detailed explanation of molecular tests is available in the Online
Supplement.
Treatments
In our institution, treatment for CLL has varied over the last two
decades. Traditionally, chlorambucil and other alkylating agents
were commonly used until the introduction of purine analogs,
mostly fludarabine and cladribine, in the 1990s. From 1995 to
2004, we conducted several trials evaluating the role of FC-mitox-
antrone,21,22 while rituximab was not generally used until 2005.17
Other treatments, such as corticosteroids, CHOP (cyclophos-
phamide, adriamycin, vincristine and prednisone) chemotherapy,
alemtuzumab, bendamustine and interferon were also used in a
small proportion of patients. For the purpose of this analysis,
patients were grouped into those who received alkylating agents
or other drugs, purine analogs without rituximab, and purine
analogs with rituximab.
Minimal residual disease evaluation
MRD was assessed using sensitive flow cytometry of peripheral
blood and/or bone marrow samples drawn 3 months after front-
line therapy. The sensitivity of this technique was determined by
dilutional studies, and established to be <10-4, as previously report-
ed.39 Patients who achieved MRD negativity had 6-monthly MRD
evaluations in peripheral blood and/or bone marrow until MRD
became positive or the disease progressed, whichever occurred
first. A detailed explanation of the method of evaluating MRD is
available in the Online Supplement.
Statistical analysis
Patients were divided into four groups based on their response:
complete response and MRD-negative (<10-4), complete response
and MRD-positive (≥10-4), partial response and no response. The
distribution of clinical and biological parameters among groups
was compared using the Fisher exact or χ2 test. Treatment-free
survival and overall survival were calculated using a landmark
analysis. All calculations were performed using either SPSS, ver-
sion 18.0, or R, version 3.0.1. Two-sided P values <0.05 were con-
sidered statistically significant. A detailed explanation of the sta-
tistical methods is available in the Online Supplement.
Results
Baseline characteristics
The median age of the entire cohort was 58 years
(range, 27-93 years), and the percentage of patients older
than 70 years was 22%. According to Döhner’s hierarchi-
cal model, 17/221 (8%) and 40/221 (18%) patients had 17p
deletion and 11q deletion, respectively. TP53 mutations
were documented in 22/193 (11%) patients tested, and 12
of these cases were found in patients who did not have a
17p deletion on the other allele. NOTCH1 and SF3B1
mutations were detected in 39/244 (16%) and 28/204
(14%) patients, respectively. Full details of these muta-
tions are shown in Online Supplementary Table S1. Other
adverse prognostic factors, including unmutated IGHV
genes and increased ZAP-70 or CD38 expression, were
observed in 151/217 (70%), 113/211 (54%) and 106/232
(46%) patients, respectively (Table 1).
Treatments and responses 
Treatment schemes included chlorambucil (n=82
patients), CHOP or CHOP-like regimens (n=24), purine
analogs as monotherapy (n=41), FC (± mitoxantrone)
(n=46), rituximab-FC (± mitoxantrone) (n=51), and others
(n=11) (Table 2). Ninety-six (38%) patients achieved a
complete response. MRD was considered negative (<10-4)
in 44 cases and positive (≥10-4) in 52 cases. In addition, 104
(41%) patients achieved a partial response and 55 (22%)
had no objective response to therapy. Table 2 displays all
response rates according to the different therapeutic regi-
mens, and Online Supplementary Table S2 shows the sensi-
tivity of the technique. MRD negativity was documented
in 31/51 (61%) patients treated with rituximab-FC(±
mitoxantrone), 11/46 (24%) patients treated with FC(±
mitoxantrone), ¼ (25%) patients treated with alemtuzum-
ab and 1/41 (2%) patients treated with purine analogs
(either fludarabine or cladribine) as monotherapy. There
were no MRD-negative responses in patients treated with
chlorambucil, CHOP or other drugs. The characteristics
associated with a higher probability of obtaining a MRD-
negative complete remission were absence of NOTCH1
mutations (P=0.005), age less than 70 years (P=0.018) and
type of therapy (alkylating agents or others versus purine
analogs versus purine analogs plus rituximab; P<0.001). Of
note, MRD status was not significantly associated with
IGHV mutation status, Binet stage, fluorescence in situ
hybridization (FISH) abnormalities, and CD38 or ZAP-70
expression (Table 1).
Treatment-free survival
The median follow-up was 73 (range 2-202), 73 (range 8-
202) and 131 (24-266) months from disease evaluation after
frontline therapy, landmark time (i.e. 9 months after initia-
tion of therapy) and diagnosis, respectively. In the whole
cohort, the median treatment-free survival for patients
achieving an MRD-negative complete response was 76
months (95% CI, 42-109), whereas that of patients with an
MRD-positive complete response was 40 months (95% CI,
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11-69), patients with a partial response 11 months (95%
CI, 7-15) and those who had no objective response 11
months (95% CI, 7-15) (P<0.001). In patients treated with
purine analogs + rituximab, the median treatment-free sur-
vival was 80 (95% CI, 36-124) months for patients who
achieved an MRD-negative complete response compared
to 53 (95% CI, 29-78) months for patients achieving an
inferior response (P=0.184). In patients treated with purine
analogs, the median treatment-free survival for the same
groups was 71 (95% CI, 17-125) and 16 (95% CI, 6-26)
months, respectively (P=0.009).
Univariate analysis revealed that the following variables
were significantly associated with a longer treatment-free
survival after front-line therapy: mutated IGHV genes
(P<0.001), absence of NOTCH1 mutations (P<0.001), nor-
mal β2-microglobulin levels (P<0.001), low ZAP-70 expres-
sion (P=0.010), absence of TP53 mutations (P=0.003),
absence of 17p deletion by FISH (P=0.018), treatment with
chemoimmunotherapy (P<0.001) and achievement of a
MRD-negative status (P<0.001) (Figure 1 and Table 3).
Cox regression analysis revealed that four variables had a
significant independent impact on treatment-free survival:
MRD-negative status [hazard ratio (HR) 3.28; 95% CI,
1.85-5.82; P<0.001], mutated IGHV genes (HR 2.11; 95%
CI, 1.41-3.15; P<0.001), and normal β2-microglobulin lev-
els (HR 1.56; 95% CI, 1.10-2.23; P=0.012) (Table 3). All
variables with a significant impact on treatment-free sur-
vival by multivariate analysis met the proportional haz-
ards assumption.
Overall survival
Patients achieving a MRD-negative complete response
had a median overall survival of 108 months (95% CI, 88-
127) compared to 113 months (95% CI not estimated) in
those who achieved a MRD-positive complete response,
62 months (95% CI, 54-70) in those who had a partial
response and 69 months (95% CI, 49-89) in patients who
did not have a response. This difference was statistically
significant (P=0.001). In patients who received purine
analgogs + rituximab, the median overall survival was not
reached for either MRD-negative or MRD-positive
patients, and there was no difference in terms of overall
survival (P=0.68). In patients treated with purine analogs,
the median overall survival was 111 months (95% CI, 96-
125) for patients with an MRD-negative complete
response compared to 93 (95% CI, 74-113) months for
patients with an MRD-positive complete response, partial
response or no response, but this difference was not statis-
tically significant (P=0.381).
Other variables associated with a significantly longer
median overall survival were mutated IGHV genes (185
versus 80 months, P=0.002), low-risk genomic aberrations
(97 versus 73 versus 52 months, P=0.001), normal β2-
microglobulin levels (105 versus 61 months, P<0.001),
absence of TP53 mutations (99 versus 52, P=0.002), age
younger than 70 years (98 versus 30 months, P<0.001) and
type of therapy (not reached versus 98 versus 63 months for
patients treated with chemoimmunotherapy, purine
Table 1.  Patients’ characteristics at diagnosis according to disease response
after front-line therapy.
Characteristics Total MRD-negative MRD-positive P value (χ2
CR CR or PR or NR or Fisher
N. (%) N. (%) N. (%) exact test)
All patients 255 (100) 44 (17) 211 (83)
Age, years (n=255) 0.018
< 70 198 (78) 40 (20) 158 (80)
≥ 70 57 (22) 4 (7) 53 (93)
Binet stage (n=255) 0.386
A 177 (69) 34 (19) 143 (81)
B 61 (24) 7 (12) 54 (88)
C 17 (7) 3 (18) 14 (82)
β2-microglobulin (n=216) 0.478
< 2.4 mg/dL 107 (50) 21 (20) 86 (80)
≥ 2.4 mg/dL 109 (50) 17 (16) 92 (84)
ZAP-70 expression (n= 211) 0.734
< 20% 98 (46) 19 (19) 79 (81)
≥ 20% 113 (54) 25 (22) 88 (78)
CD38 expression (n=232) 0.401
< 30% 126 (54) 21 (17) 105 (83)
≥ 30% 106 (46) 23 (22) 38 (78)
FISH aberrations (n=221) 0.324
Low risk* 160 (74) 31 (19) 133 (81)
11q deletion 40 (18) 11 (28) 29 (72)
17p deletion 17 (8) 2 (12) 15 (88)
TP53 gene (n=193) 0.172
Unmutated 171 (87) 40 (23) 131 (77)
Mutated 22 (11) 2 (9) 20 (91)
IGHV gene (n=217) 0.193
Unmutated 151 (70) 33 (22) 118 (78)
Mutated 66 (30) 9 (14) 57 (86)
NOTCH1 gene (n=244) 0.005
Unmutated 205 (84) 43 (21) 162 (79)
Mutated 39 (16) 1 (3) 38 (97)
SF3B1 gene (n=204) 0.805
Unmutated 176 (86) 38 (22) 138 (78)
Mutated 28 (14) 5 (18) 23 (82)
MYD88 gene (n=243) 0.075
Unmutated 237 (97) 41 (17) 196 (83)
Mutated 6 (3) 3 (50) 3 (50)
Treatment (n=255) <0.001
Chemoinmunotherapy 51 (20) 31 (61) 20 (39)
PA ± AA 87 (34) 12 (14) 75 (86)
AA or others 117 (46) 1 (1) 116 (99)
PR: partial remission; MRD: minimal residual disease; CR: complete remission; NR: no response;
FISH: fluorescent in-situ hybridization; IGHV: immunoglobulin heavy chain; PA: purine analogs;
AA: alkylating agents. *Low-risk disease by FISH was defined by the absence of 17p or 11q dele-
tions.
Table 2.  First-line treatment and response to therapy.
Therapy All patients MRD-negative MRD-positive
(N=255) CR CR PR NR
N. (%) N. (%) N. (%) N. (%)
Chlorambucil 82 0 (0) 6 (7) 46 (56) 30 (37)
R-FC / R-FCM 51 31 (61) 13 (25) 3 (6) 4 (8)
FC/ FCM 46 11 (24) 18 (39) 17 (37) 0 (0)
Cladribine/ 41 1 (2) 9 (22) 23 (56) 8 (20)
fludarabine 
monotherapy
CHOP, CHOP-like 24 0 (0) 4 (17) 11 (46) 9 (37)
or bendamustine
Others 11 1 (10) 2 (18) 4 (36) 4 (36)
NR: no response; PR: partial remission; MRD: minimal residual disease; CR: complete remission;
NR: no reponse or progression; FC: fludarabine and cyclophosphamide; FCM: fludarabine,
cyclophosphamide and mitoxantrone; R: rituximab; CHOP: cyclophosphamide, adriamycin, vin-
cristine and prednisone.
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analogs and alkylating agents or others, respectively,
P=0.001) (Figure 2). Other variables, such as CD38 or
ZAP-70 expression, Binet stage, or the presence of
NOTCH1 or SF3B1 mutations had no significant impact
on overall survival. Cox regression analysis revealed that
five variables had a favorable impact on overall survival:
young age (HR 1.05; 95% CI 1.03-1.06; P<0.001), mutated
IGHV genes (HR 2.06; 95% CI 1.35-3.13; P=0.001), normal
β2-microglobulin levels (HR 1.72; 95% CI 1.20-2.47;
P=0.003), absence of TP53 mutations (HR 2.39; 95% CI
1.48-3.85; P<0.001) and achievement of an MRD-negative
status (HR 2.12; 95% CI 1.16-3.88; P=0.014) (Table 3). All
variables with a significant impact on overall survival by
multivariate analysis met the proportional hazards
assumption.
Outcome of patients achieving minimal residual 
disease-negative status
Of 44 patients who achieved MRD negativity, 18 (41%)
patients remained negative at last follow-up and 26 (59%)
became MRD-positive. Moreover, 12/44 (27%) patients
have required second-line treatment so far. The median
times from disease evaluation to MRD positivity and sec-
ond-line therapy were 37 months (95% CI, 33-41) and 73
months (95% CI, 59-97), respectively. 
The presence of adverse FISH abnormalities (i.e. 17p or
11q deletion) was the only covariate significantly associat-
ed with a shorter time to MRD positivity (P=0.024).
Moreover, adverse FISH and TP53 mutations were both
independently associated with a shorter time to second-
line therapy (P=0.008 and P=0.006, respectively).
Discussion
Therapy for CLL has notoriously improved in the last
decades. Alkylating agents traditionally used in CLL, such
as chlorambucil, only achieved a 2-10% complete
response rate,40 with no MRD-negative responses.41 Purine
analogs significantly improved complete response rates
but still less than 10% of patients achieved a MRD-nega-
tive status when these agents were given as
monotherapy.42 Combination chemotherapy (i.e. FC, with
or without mitoxantrone) improved responses even more,
obtaining complete response rates of 20-40%40 and, for the
first time, a quarter of patients treated with these combi-
nations did not have detectable MRD at the time of
response evaluation.18,22 Unfortunately, none of these ther-
apeutic options had a significant impact on overall sur-
vival40 and, perhaps, the reason was that the percentage of
patients obtaining MRD-negative responses was insuffi-
cient. With the advent of rituximab-containing combina-
tions (i.e. chemoimmunotherapy), complete response
rates have doubled, and so have MRD-negative rates.17,18,20
Not surprisingly, several single-center and epidemiological
studies have confirmed that front-line chemoimmunother-
apy prolongs the overall survival of patients with CLL
compared to that of historical cohorts of patients treated
without rituximab.24,43 Moreover, a phase III randomized
trial recently showed that the addition of rituximab to FC
front-line chemotherapy prolonged the overall survival
compared to FC alone,44 and also that MRD status after
treatment was one of the most important predictors of
survival.18 Nevertheless, very few studies have performed
a multivariate analysis evaluating the impact of MRD in
R. Santacruz et al.
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Figure 1. Treatment-free survival from landmark according to: (A)
response to therapy; (B) β2-microglobulin levels; and (C) IGHVmutational
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the context of other prognostic biomarkers.
In the present study, we evaluated the prognostic value
of MRD after first-line therapy in a group of patients with
a very detailed prognostic evaluation, including assess-
ment of TP53, NOTCH1 and SF3B1 mutations. This is
particularly relevant since one of the major criticisms
made to the implementation of MRD assessment in CLL
is that patients in whom MRD can be eradicated could
simply be biologically distinct from the remainder and,
possibly, have a better prognosis.18,23 In this study, we have
confirmed that MRD negativity was a consistent predictor
of both treatment-free survival and overall survival togeth-
er with other well characterized prognostic factors, such
as IGHV mutation status and β2-microglobulin serum con-
centration. Patients achieving a MRD-negative complete
response had the longest median treatment-free survival
(76 months) compared to those who achieved a MRD-
positive complete response, a partial response or who did
not respond (40, 11 and 11 months, respectively).
Moreover, and in contrast to the British study,23 the differ-
ence in treatment-free survival between patients obtaining
a MRD-positive complete response and those achieving a
partial response was statistically significant (40 versus 11
months, P<0.001), probably because of the higher statisti-
cal power of our study. This result is, however, not sur-
prising since in almost any malignancy the deeper the
MRD in CLL
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Table 3.  Univariate and multivariate analyses of the effect of MRD and other prognostic factors on treatment-free and overall survival.
Treatment-free survival Overall survival
Univariate analysis (Kaplan-Meier Multivariate analysis Univariate analysis Multivariate analysis 
and log-rank test) (Cox regression after multiple (Kaplan-Meier and (Cox regression after multiple
imputation) log-rank test) imputation)
Variable Median 95% CI P value HR 95% CI P value Median 95% CI P value HR 95% CI P value
(months) (months)
Age, years
< 70 28 21-36 < 0.001 1.00 0.99-1.02 0.503 98 88-108 < 0.001 1.05 1.03-1.06 < 0.001
≥ 70 11 6-17 30 11-49
Binet stage
A 30 20-41 0.005 1.14 .87-1.52 0.334 90 68-113 0.551 - - -
B 18 8-22 87 67-108
C 8 3-14 58 42-74
β2 microglobulin (mg/dL)
< 2.4 37 25-49 < 0.001 1.56 1.10-2.23 0.012 105 85-125 < 0.001 1.72 1.20-2.47 0.003
≥ 2.4 14 7-21 61 51-70
FISH
Low risk* 30 20-40 0.018 1.18 0.83-1.71 0.355 97 83-111 0.001 1.47 0.96-2.24 0.075
11q deletion 25 18-33 73 39-106
17p deletion 15 0-31 52 42-61
TP53
Unmutated 32 23-42 0.003 1.17 0.73-1.87 0.512 99 82-117 0.002 2.39 1.48-3.85 <0.001
Mutated 11 0-30 52 38-65
ZAP70 expression
Low 42 29-55 0.010 1.02 0.73-1.43 0.895 101 87-116 0.152 - - -
High 19 11-27 82 61-103
IGHV gene
Unmutated 20 13-26 <0.001 2.11 1.41-3.15 < 0.001 80 60-101 0.002 2.06 1.35-3.13 0.001
Mutated 58 32-80 185 85-284
NOTCH1
Unmutated 30 21-39 < .001 1.43 .96-2.13 0.080 97 84-109 0.062 - - -
Mutated 8 0-17 58 45-72
SF3B1
Unmutated 28 18-38 0.201 - - - 93 78-109 0.747 - - -
Mutated 23 15-32 99 67-132
MRD
Negative 76 42-109 < 0.001 3.28 1.85-5.82 < 0.001 108 88-127 0.012 2.13 1.16-3.88 0.014
Positive 16 10-22 78 62-95
Treatment
AA or others 13 6-20 <0.001 1.29 0.99-1.02 0.054 65 52-78 0.001 1.26 0.90-1.77 0.183
PA 23 15-31 98 74-122
PA+R 80 38-123 NR -
PR: partial remission; MRD: minimal residual disease; CR: complete remission; ND; no response or disease progression; FISH: fluorescent in-situ hybridization; IGHV: immunoglob-
ulin heavy chain; PA: purine analogs; AA: alkylating agents; R: rituximab; NR: not reached. *Low risk disease by FISH was defined by the absence of 17p or 11q deletions.
Statistically significant results are shown in bold.
response obtained with therapy, the longer the patient
remains in remission and, therefore, free of therapy.29,30
MRD status also had a significant impact on overall sur-
vival, and this effect, too, was independent of other well-
established prognostic factors. In keeping with the results
of both the British and German studies,18,23 patients obtain-
ing MRD negativity at the 10-4 level had a significantly
longer overall survival than that of patients obtaining an
inferior response (not reached versus 81 months, P=0.007).
When we specifically evaluated patients who responded
to therapy, there was a trend towards a longer overall sur-
vival for MRD-negative patients (108 versus 78 months,
P=0.012), but this significant difference was lost when
patients achieving a MRD-negative complete response
were compared to those achieving a MRD-positive com-
plete response (P=0.82). These results indicate that MRD
negativity appeared at least as relevant to the survival of
the patients as obtaining a complete response by NCI-WG
criteria, and possibly more important than the treatment
they received to attain that goal.18 Furthermore, MRD sta-
R. Santacruz et al.
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Figure 2. Overall survival from landmark according to: (A) response
to therapy, (B) age, (C) β2-microglobulin levels, (D) IGHV mutational
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tus was significantly more relevant than other well-char-
acterized prognostic markers, including FISH aberrations,
ZAP-70 expression or gene mutations (NOTCH1 or
SF3B1). Another interesting finding of our study was the
fact that TP53 mutations had an independent prognostic
impact on overall survival even when evaluated alongside
FISH aberrations, confirming results from other groups
and suggesting that TP53 sequencing should be incorpo-
rated into the laboratory work-up of patients with
CLL.5,45-47
Current clinical guidelines for the management of CLL
do not recommend the evaluation of MRD in routine prac-
tice, but only within clinical trials that “aim toward
achieving long-lasting complete responses”.36 We believe
that there is already enough evidence to recommend the
assessment of MRD status in all patients who achieve a
complete remission after front-line therapy since the prog-
nostic power of this test is at least comparable to that of
other tests generally recommended by current guidelines,
such as FISH cytogenetics.36 MRD status after therapy
could be used in deciding how closely a patient should be
followed-up, and also in selecting those patients who
might benefit from inclusion in clinical trials evaluating
maintenance or consolidation strategies.48,49 Regarding the
technique used to evaluate MRD in CLL, MRD-flow
cytometry does not require pre-treatment samples and is
becoming the technique of choice in view of its sensitivity
and reproducibility, even in the context of multicenter tri-
als.19,50 Furthermore, several problems associated with
four-color panels, such as the large amounts of time and
sample required for an accurate analysis of patients with
low level disease, have been partially circumvented with
the advent of modern six-color combinations. With these
new advances, MRD-flow could be implemented in most
diagnostic laboratories with additional savings in terms of
time, labor and reagents.50
There are, however, several considerations that should
be highlighted. First, MRD-flow cytometry has changed
several times over the years and has only been standard-
ized in the last decade, even though its sensitivity has
remained constant. Moreover, treatment groups were het-
erogeneous and relatively small, compared to those in
recent randomized trials, due to the retrospective nature
of this study, and this might have reduced the statistical
power of the variable “treatment” in our multivariate
models. Furthermore, we only had MRD results for
patients who achieved a complete response and, there-
fore, we were unable to analyze the outcome of patients
with MRD-negative partial responses together with those
with MRD-negative complete responses as recommended
by other groups.18,28
In conclusion, in this study we observed that, for
patients with CLL requiring front-line therapy, achieve-
ment of a MRD-negative status is associated with signifi-
cantly prolonged treatment-free survival irrespective of
other prognostic markers or treatment given. We also
observed a significant benefit in terms of overall survival,
but this effect was less clear. These results could have
potential implications when deciding the most appropri-
ate treatment for patients with the disease, and could also
set the stage for future MRD-directed therapy in CLL.
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